Alnylam Pharmaceuticals (ALNY) revenue: $3.7B
Alnylam Pharmaceuticals reported $3.7B of revenue for the year ended Dec 31, 2025, up 65.2% from $2.2B a year earlier.
From Alnylam Pharmaceuticals's filings with the SEC · Read the filing · ALNY stock page
Alnylam Pharmaceuticals revenue by year
#854 of 3,622 US companies by revenue · See the full ranking
| Year ended | Revenue | Change |
|---|---|---|
| Dec 31, 2025 | $3.7B | +65% |
| Dec 31, 2024 | $2.2B | +23% |
| Dec 31, 2023 | $1.8B | +76% |
| Dec 31, 2022 | $1B | +23% |
| Dec 31, 2021 | $844M | – |
Revenue of similar companies
Companies in the same industry as Alnylam Pharmaceuticals, by SEC industry code, with the closest revenue. Each name opens the same page for that company.
| Company | Revenue, latest year | Year ended |
|---|---|---|
| Elanco Animal Health | $4.7B | Dec 31, 2025 |
| Jazz Pharmaceuticals | $4.3B | Dec 31, 2025 |
| PERRIGO | $4.3B | Dec 31, 2025 |
| Alnylam Pharmaceuticals | $3.7B | Dec 31, 2025 |
| Biomarin Pharmaceutical | $3.2B | Dec 31, 2025 |
| United Therapeutics | $3.2B | Dec 31, 2025 |
| Amneal Pharmaceuticals | $3B | Dec 31, 2025 |
Questions and answers
What is Alnylam Pharmaceuticals's revenue?
Alnylam Pharmaceuticals reported $3.7B of revenue for the year ended Dec 31, 2025, up 65.2% from $2.2B a year earlier.
Numbers as reported in Alnylam Pharmaceuticals's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology